Cell and gene therapies have the potential to revolutionize treatment of a wide range of diseases. With six new therapies approved in 2022, including the first allogeneic T-cell therapy, and at least as many slated for approval this year, the sector is poised for rapid growth. This innovation comes with challenges, though, and many consider 2023 to be a seminal year for establishing a strong foothold for advanced therapies in mainstream medicine.
On May 11, 2023, Precision ADVANCE, the Center for Breakthrough Medicines, and the Alliance for Regenerative Medicine co-sponsored the second annual Cell & Gene Day, hosted by Endpoint News. Throughout this event, over 25 successful innovators from across the advanced therapy sector shared fresh ideas and insights on overcoming critical challenges in bringing life-saving therapies to patients in need. This white paper is based on a discussion moderated by Anshul Mangal, President of Precision ADVANCE and Project Farma, and the following panelists:
- James M. Wilson, MD, PhD, Professor of Medicine and Pediatrics and Director of the Gene Therapy Program, University of Pennsylvania
- Bruce L. Levine, PhD, Barbara and Edward Netter Professor in Cancer Gene Therapy and Founding Director of the Clinical Cell and Vaccine Production Facility, University of Pennsylvania
- Deb Phippard, PhD, Chief Scientific Officer, Precision for Medicine
- Kiran Reddy, MD, Senior Managing Director, Blackstone
